Full Answer
Is GTXi a good long-term investment?
According to our live Forecast System, GTx, Inc. stock is an awesome long-term (1-year) investment*. "GTXI" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "GTXI" projections.
How often do you update the GTXi stock predictions?
"GTXI" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "GTXI" projections. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like GTx, Inc..
Are earnings expected to increase or decrease for GTX stock?
Earnings for GTX are expected to decrease in the coming year, from ($0.97) to ($1.11) per share. The P/E ratio of GTX is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is GTX's GTXi in a bearish market environment?
According to present data GTx's GTXI shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Currently there seems to be a trend where stocks in the Other Health Technology sector (s) are not very popular in this period.
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnin...
Who are GTX's key executives?
GTX's management team includes the following people: Dr. Robert James Wills B.S. , M.S., Ph.D., Exec. Chairman (Age 65) Mr. Marc S. Hanover , C...
Who are some of GTX's key competitors?
Some companies that are related to GTX include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceutical...
What other stocks do shareholders of GTX own?
Based on aggregate information from My MarketBeat watchlists, some companies that other GTX investors own include Corbus Pharmaceuticals (CRBP) ,...
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $1.23.
How much money does GTX make?
GTX (NASDAQ:GTXI) has a market capitalization of $29.58 million. The biopharmaceutical company earns $-38.42 million in net income (profit) each ye...
How many employees does GTX have?
GTX employs 21 workers across the globe.
How can I contact GTX?
GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103 . The official website for GTX is www.gtxinc.com . The biopharmaceutical...
What happened
Shares of GTx (NASDAQ: GTXI) were obliterated today, falling as much as 92.9% by 3 p.m. EDT, after the pharma company announced that its only drug candidate failed a mid-stage clinical trial. Enobosarm, being evaluated as a potential treatment for stress urinary incontinence, did not meet its primary endpoint in a phase 2 trial.
So what
The near-total collapse of GTx stock today is a reminder that being a one-trick pony in pharma is risky. Are there any reasons for optimism going forward?
Now what
Today is very disappointing for shareholders who were hoping for a successful outcome for enobosarm. And without any other drugs in the pike and the next clinical drug candidates still at least one year away from entering early-stage trials, there's not much of a reason for investors to own GTx stock in their portfolios right now.
What happened
Shares of GTx (NASDAQ: GTXI) were obliterated today, falling as much as 92.9% by 3 p.m. EDT, after the pharma company announced that its only drug candidate failed a mid-stage clinical trial. Enobosarm, being evaluated as a potential treatment for stress urinary incontinence, did not meet its primary endpoint in a phase 2 trial .
So what
The near-total collapse of GTx stock today is a reminder that being a one-trick pony in pharma is risky. Are there any reasons for optimism going forward?
Now what
Today is very disappointing for shareholders who were hoping for a successful outcome for enobosarm. And without any other drugs in the pike and the next clinical drug candidates still at least one year away from entering early-stage trials, there's not much of a reason for investors to own GTx stock in their portfolios right now.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
Signals & Forecast
There are mixed signals in the stock today. The GTx stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
GTx finds support from accumulated volume at $1.72 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is GTx stock A Buy?
GTx holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About GTx
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What happened
Shares of GTx (NASDAQ: GTXI) were obliterated today, falling as much as 92.9% by 3 p.m. EDT, after the pharma company announced that its only drug candidate failed a mid-stage clinical trial. Enobosarm, being evaluated as a potential treatment for stress urinary incontinence, did not meet its primary endpoint in a phase 2 trial .
So what
The near-total collapse of GTx stock today is a reminder that being a one-trick pony in pharma is risky. Are there any reasons for optimism going forward?
Now what
Today is very disappointing for shareholders who were hoping for a successful outcome for enobosarm. And without any other drugs in the pike and the next clinical drug candidates still at least one year away from entering early-stage trials, there's not much of a reason for investors to own GTx stock in their portfolios right now.
GTXI Target Price
GTXI price target in 14 days: 1.377 USD* upside and 1.145 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
GTx, Inc. ( GTXI ) Stock Market info
Recommendations: Buy or sell GTx stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the GTx share forecasts, stock quote and buy / sell signals below. According to present data GTx's GTXI shares and potentially its market environment have been in bearish cycle last 12 months (if exists).
Garrett Motion (GTX) Q4 Earnings Top Estimates
Garrett Motion (GTX) delivered earnings and revenue surprises of 31.58% and 0.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Garrett Motion Reports Fourth Quarter and Full Year 2021 Financial Results
Fourth Quarter 2021 Highlights Reported net sales totaled $862 million, down 14% on a GAAP basis and 13% at constant currency*Net income totaled $128 million; Adjusted net income* was $78 millionAdjusted EBITDA* totaled $129 million; Adjusted EBITDA margin* improved to 15.0%Net cash provided by operating activities totaled $136 millionAdjusted free cash flow* totaled $151 million; Adjusted free cash flow conversion rate* was 194% Full Year 2021 Highlights Net sales totaled $3,633 million, up 20%.
Garrett Motion to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Monday, February 14
ROLLE, Switzerland, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Garrett Motion Inc.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Monday, February 07, 2022, and so far it has risen 5.42%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss
GBX International Group Inc. finds support from accumulated volume at $0.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is GBX International Group Inc. stock A Buy?
GBX International Group Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
